{"product_id":"global-microbiome-therapeutics-market-growth-status-and-outlook-2023-2029","title":"Global Microbiome Therapeutics Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Microbiome Therapeutics Market Growth (Status and Outlook) 2023-2029\u003c\/p\u003e\n\n\u003cp\u003eThe human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).\u003c\/p\u003e \n\n\u003cp\u003eThese microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.\u003c\/p\u003e \n\n\u003cp\u003eAn ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Microbiome Therapeutics Industry Forecast” looks at past sales and reviews total world Microbiome Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Microbiome Therapeutics sales for 2023 through 2029. With Microbiome Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Microbiome Therapeutics industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Microbiome Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Microbiome Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Microbiome Therapeutics market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Microbiome Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Microbiome Therapeutics.\u003c\/p\u003e\n\n\u003cp\u003eThe global Microbiome Therapeutics market size is projected to grow from US$ 89 million in 2022 to US$ 916.3 million in 2029; it is expected to grow at a CAGR of 39.5% from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eThe Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R\u0026amp;D Investmen for CDI is about 52%.\u003c\/p\u003e\n\n\u003cp\u003eFor Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.\u003c\/p\u003e\n\n\u003cp\u003eNorth American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.\u003c\/p\u003e \n\n\u003cp\u003eMarket competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Microbiome Therapeutics market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003c\/p\u003e\n\n \u003cp\u003eUpper GIT\u003c\/p\u003e\n\n \u003cp\u003eLower GIT\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003c\/p\u003e\n\n \u003cp\u003eC. difficile Infection (CDI)\u003c\/p\u003e\n\n \u003cp\u003eInflammatory Bowel Disease (IBD)\u003c\/p\u003e\n\n \u003cp\u003eOrphan Drug\u003c\/p\u003e\n\n \u003cp\u003eImmuno-oncology\u003c\/p\u003e\n\n \u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003c\/p\u003e\n\n \u003cp\u003eAmericas\u003c\/p\u003e\n\n \u003cp\u003eUnited States\u003c\/p\u003e\n\n \u003cp\u003eCanada\u003c\/p\u003e\n\n \u003cp\u003eMexico\u003c\/p\u003e\n\n \u003cp\u003eBrazil\u003c\/p\u003e\n\n \u003cp\u003eAPAC\u003c\/p\u003e\n\n \u003cp\u003eChina\u003c\/p\u003e\n\n \u003cp\u003eJapan\u003c\/p\u003e\n\n \u003cp\u003eKorea\u003c\/p\u003e\n\n \u003cp\u003eSoutheast Asia\u003c\/p\u003e\n\n \u003cp\u003eIndia\u003c\/p\u003e\n\n \u003cp\u003eAustralia\u003c\/p\u003e\n\n \u003cp\u003eEurope\u003c\/p\u003e\n\n \u003cp\u003eGermany\u003c\/p\u003e\n\n \u003cp\u003eFrance\u003c\/p\u003e\n\n \u003cp\u003eUK\u003c\/p\u003e\n\n \u003cp\u003eItaly\u003c\/p\u003e\n\n \u003cp\u003eRussia\u003c\/p\u003e\n\n \u003cp\u003eMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n \u003cp\u003eEgypt\u003c\/p\u003e\n\n \u003cp\u003eSouth Africa\u003c\/p\u003e\n\n \u003cp\u003eIsrael\u003c\/p\u003e\n\n \u003cp\u003eTurkey\u003c\/p\u003e\n\n \u003cp\u003eGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003c\/p\u003e\n\n \u003cp\u003eSeres Therapeutics\u003c\/p\u003e\n\n \u003cp\u003eAssembly Biosciences\u003c\/p\u003e\n\n \u003cp\u003eSynthetic Biologics\u003c\/p\u003e\n\n \u003cp\u003eInterxon\u003c\/p\u003e\n\n \u003cp\u003ePureTech\u003c\/p\u003e\n\n \u003cp\u003eSynlogic\u003c\/p\u003e\n\n \u003cp\u003eEnterome BioScience\u003c\/p\u003e\n\n \u003cp\u003e4D Pharma\u003c\/p\u003e\n\n \u003cp\u003eSecond Genome\u003c\/p\u003e\n\n \u003cp\u003eAOBiome\u003c\/p\u003e\n\n \u003cp\u003eC3 Jian\u003c\/p\u003e\n\n \u003cp\u003eRebiotix\u003c\/p\u003e\n\n \u003cp\u003eMicroBiome Therapeutics LLC\u003c\/p\u003e\n\n \u003cp\u003eMetabiomics\u003c\/p\u003e\n\n \u003cp\u003eRitter Pharmaceuticals\u003c\/p\u003e\n\n \u003cp\u003eSymberix\u003c\/p\u003e\n\n \u003cp\u003eOpenBiome\u003c\/p\u003e\n\n \u003cp\u003eAzitra\u003c\/p\u003e\n\n \u003cp\u003eSymbiotix Biotherapies\u003c\/p\u003e\n\n \u003cp\u003eOsel\u003c\/p\u003e\n\n \u003cp\u003eMetabogen\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 124 Pages \/ MCW16225953","offer_id":47640100208946,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-microbiome-therapeutics-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}